Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
J Med Virol ; 94(6): 2598-2606, 2022 06.
Article in English | MEDLINE | ID: mdl-35149996

ABSTRACT

Coxsackievirus B2 (CVB2) is an enterovirus B (EV-B) species and can cause aseptic meningitis, myocarditis and hand, foot, and mouth disease (HFMD). We characterized a novel CVB2 (YN31V3) associated with HFMD in Yunnan, Southwest China, in 2019. Although YN31V3 and other Mainland China epidemic strains mainly belonged to genotype C, YN31V3 formed an independent branch. The genome sequence of the strain YN31V3 from this study showed a 12.91% nucleotide difference to its closest strain RW41-2/YN/CHN/2012. Recombination analyses showed that the newly isolated YN31V3 was probably a recombinant, which was closely related to CVB2 strains in the genomic P1 region and other EV-B strains in the P2 and P3 regions, respectively. YN31V3 strain had a temperature-sensitive phenotype. The challenge of suckling BALB/c mice with YN31V3 could cause symptoms of disease and severe pathological lesions.


Subject(s)
Enterovirus , Hand, Foot and Mouth Disease , Animals , China/epidemiology , Enterovirus/genetics , Enterovirus B, Human , Genome, Viral , Genotype , Hand, Foot and Mouth Disease/epidemiology , Hand, Foot and Mouth Disease/genetics , Humans , Mice , Phylogeny
2.
J Virol Methods ; 301: 114408, 2022 03.
Article in English | MEDLINE | ID: mdl-34896455

ABSTRACT

Immunization is the most effective way to respond to an influenza epidemic. To produce Vero cell-derived influenza vaccines, a more efficient, stable and economical purification process is required. In this study, we purified the H7N9 influenza virus grown in Vero cells that were cultured in a serum-free medium by using a combination of anion exchange chromatography (AEC) and ligand-activated core chromatography (LCC), which avoids the virus capture step. After purification, 99.95 % host cell DNA (hcDNA) (final concentration: 28.69 pg/dose) and 98.87 % host cell protein (HCP) (final concentration: 28.28 ng/dose) were removed. The albumin content was 11.36 ng/dose. All these remnants met the current Chinese Pharmacopoeia and WHO requirements. The final virus recovery rate was 58.74 %, with the concentration of hemagglutinin recorded at 132.12 µg/mL. The flow-through chromatography purification process represents an alternative to the existing processes for cell-derived influenza viruses and might be suitable for the purification of other viruses as well.


Subject(s)
Influenza A Virus, H7N9 Subtype , Influenza Vaccines , Influenza, Human , Animals , Chlorocebus aethiops , Chromatography/methods , Hemagglutinin Glycoproteins, Influenza Virus , Humans , Influenza A Virus, H7N9 Subtype/genetics , Influenza, Human/prevention & control , Vero Cells
SELECTION OF CITATIONS
SEARCH DETAIL
...